Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.
24 patients with a median of 3 prior chemotherapy regimens were treated in our department with cisplatin 20 mg/m2 (with pre- and posthydration) and 5-fluorouracil 200 mg/m2 i.v. on day 1-5, every three weeks. 23 patients are evaluable; one had early death. 4 patients (17%) achieved a partial response, 8 had stable disease, and 11 progressed. Toxicity observed was moderate and no renal toxicity was noted. This study therefore shows tolerable toxicity but limited usefulness of adding cisplatin to 5-fluorouracil according to this schedule in these highly pretreated patients.
Amoroso
D
D
Istituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica, Genova, Italy.
Pronzato
P
P
Bertelli
G
G
Gallotti
P
P
Pastorino
G
G
Cusimano
M P
MP
Merlano
M
M
Conte
P F
PF
Rosso
R
R
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged
D002945:Cisplatin; D005472:Fluorouracil